Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Investors Wake Up To Success Of Idorsia Sleep Drug

Positive Phase III Data For Daridorexant

Executive Summary

The Swiss biotech says that a late-stage trial of the dual orexin receptor antagonist daridorexant is the first study to demonstrate an insomnia product that can improve how the patient feels during the day, as well as aiding sleep at night.

You may also be interested in...



Finance Watch: Investors Bet Billions On Big Biopharma Offerings

Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.

Novartis Eyes Gene Therapy Growth With Vedere Acquisition

The Swiss major is paying up to $280m to buy Vedere Bio, which has developed photoreceptor-protein based optogenetic therapies that are delivered to the retina intravitreally to restore vision.

Sobi Ramps Up In Rare Diseases With Apellis Deal

Sobi is paying big bucks to tap into the potential of Apellis's pegcetacoplan, a targeted C3 therapy for the treatment of multiple rare diseases with high unmet need which the partners say impact more than 275,000 patients globally.

Topics

Related Companies

UsernamePublicRestriction

Register

ID1132375

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel